Novartis Venture Funds leads first round of funding for NanoPowers
Novartis Venture Funds, the $750m corporate venturing division of pharmaceutical firm Novartis, has led a SWF5m ($4.5m) first round of funding for NanoPowers, a Switzerland-based medical device company that makes artificial muscles.
Initiative Capital Romandie, a SWF15m VC fund run by Switzerland’s DEFI Gestion private equity group and which last invested in Endosense last year, and Gran Plasa, a local private investment fund, also joined Novartis in the series A financing of NanoPowers.
Novartis Venture Funds was also the seed…
